| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. |
| 28 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS AMENDMENT NO. 1 TO CREDIT AGREEMENT AND WAIVER (this “Amendment”) is made and entered into as of October 28, 2026, by and among SANUWAVE HEALTH, INC., a Nevada corporation (the “Company”), SANUWAVE, INC., a Delaware corporation, the... |
| 25 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 23, 2026, Sanuwave Health, Inc., a Nevada corporation (the “Company”), received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, for th... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. |
| 13 Jul 2026 |
8-K: Results of Operations and Financial Condition
Sanuwave announces preliminary, unaudited revenues of $9.6 million to $9.8 million |
| 16 Jun 2026 |
8-K: Regulation FD Disclosure
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million |
| 15 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Sanuwave Health, Inc. (the “Company”) held its 2026 annual meeting of stockholders. The following matters (the “Proposals”) were voted upon by the stockholders with the final voting results as shown: |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. |
| 16 Apr 2026 |
8-K: Results of Operations and Financial Condition
Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. |
| 13 Mar 2026 |
8-K: Non-Reliance on Previously Issued Financial Statements
In connection with the preparation of the 2025 consolidated financial statements of Sanuwave Health, Inc. (the “Company”), the Company engaged a third party to conduct a sales and use tax nexus study. Management used this third party rep... |
| 07 Nov 2025 |
8-K: Results of Operations and Financial Condition
Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2025. This represents the highest quarterly revenues in Company history. |
| 30 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
I. I (Andrew Walko) was employed by SANUWAVE (as defined below) pursuant to the terms of an offer letter dated July 18, 2023 (the “Employment Agreement”). |
| 01 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 25, 2025, Daniel Coyle was appointed the Chief Operating Officer of Sanuwave Health, Inc. (the “Company”). Mr. Coyle, age 35, was the Company’s Vice President of Engineering and Operations from October 2024 through September... |
| 26 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
JPMORGAN CHASE BANK, N.A.,as Sole Bookrunner and Sole Lead Arranger |
| 21 Aug 2025 |
8-K: Other Events
As previously disclosed, on March 6, 2024, Sanuwave, Inc. entered into an exclusive license and option agreement with a third-party licensee (the “Licensee”) in connection with a portfolio of Sanuwave, Inc. patents related to the field o... |
| 20 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1.Purpose. The purpose of the SANUWAVE Health, Inc. 2024 Equity Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of responsibility with the Company, to provide additional incentives to them ... |
| 08 Aug 2025 |
8-K: Results of Operations and Financial Condition
Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. |
| 31 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
I.I Nanci Gilmore was employed by SANUWAVE (as defined below) until my employment was terminated involuntarily without cause effective 5/30/2025 (my “Separation Date”). |
| 14 Jul 2025 |
8-K: Results of Operations and Financial Condition
Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. |
Loading...